Voltage-gated calcium channel type 2 (CaV2) (CaV2)

Voltage-gated calcium channels (VGCCs) involved in presynaptic glutamate release primarily belong to the CaV2 subfamily, including P/Q-type (CaV2.1) and N-type (CaV2.2) channels (Catterall, 2011, Cold Spring Harb Perspect Biol). These channels are localized at the presynaptic active zone, where they couple action potential-induced depolarization to the rapid influx of calcium ions. This localized calcium transient triggers the fusion of glutamate-containing synaptic vesicles with the presynaptic membrane, a process essential for excitatory neurotransmission in the brain and spinal cord (Zamponi et al., 2015, Pharmacol Rev). Dysregulation of these channels, such as gain-of-function mutations or autoantibody-mediated inhibition, is implicated in neurological disorders like familial hemiplegic migraine, episodic ataxia, and Lambert-Eaton myasthenic syndrome (UniProt O00555, Q00975). Therapeutically, these channels are targeted to modulate neurotransmitter release in conditions of hyperexcitability or chronic pain. For instance, ziconotide is a selective N-type calcium channel blocker used for refractory chronic pain, while gabapentinoids like pregabalin bind to the alpha-2-delta auxiliary subunits to modulate channel trafficking and function, effectively treating neuropathic pain and epilepsy (StatPearls NBK482238). Safety concerns associated with targeting these channels include central nervous system effects such as dizziness, cognitive impairment, and psychiatric disturbances, reflecting the widespread role of these channels in normal brain function (FDA Label for Prialt and Lyrica).

Other names

N-type calcium channelP/Q-type calcium channelR-type calcium channelPresynaptic voltage-gated calcium channelHigh-voltage activated calcium channelCACNA1ACACNA1BCACNA1E

Inhibition of calcium influx through presynaptic voltage-gated channels (primarily CaV2.1 and CaV2.2), which prevents the calcium-dependent fusion of glutamate-containing vesicles with the presynaptic membrane, thereby reducing excitatory neurotransmission.